Table 2. Isoniazid susceptibility, treatment regimen and duration, and treatment outcome in the nine study patients with disputed rpoB mutations.

Patient No.	Age (yr)	Sex	INHsusceptibility: MTBDRplus assay	INHsusceptibility: DST	Initial regimen	Duration of first regimen (mo)	Subsequent regimen	Duration of subsequent regimen (mo)	Treatment outcome	1 Year recurrence
1	43	Male	Resistant	Resistant	RIF, EMB, PZA	4	MXF, KM, PTH, CS, PAS	17	Cured	No recurrence
2	50	Male	Susceptible	Susceptible	INH, RIF, PZA	6		-	Cured	No recurrence
3	52	Male	Susceptible	Resistant	INH, RIF, EMB, PZA	5	MXF, KM, PTH, CS, PAS	13	Cured	No recurrence
4	56	Male	Susceptible	Resistant	INH, HD-RIF, EMB	1	MXF, HD-RIF, EMB	11	Cured	No recurrence
5	59	Male	Susceptible	Susceptible	INH, RIF, EMB, PZA	2	INH, HD-RIF	8	Treatment completed	No recurrence
6	24	Female	Resistant	Resistant	LVFX, KM, PZA, PTH, CS	14	-	-	Cured	No recurrence
7	39	Female	Resistant	Resistant	MXF, KM, PZA, PTH, CS	8	-	-	Treatment failed	N/A
8	69	Female	Resistant	Resistant	LVFX, KM, PZA, PTH, PAS	3	MXF, RIF, CS, AMOX	9	Cured	No recurrence
9	55	Male	Resistant	Resistant	INH, RIF, PZA, CS	0.5	LZD, PZA, CS	-	On treatment	N/A

INH: isoniazid; DST: drug susceptibility test; RIF: rifampicin; EMB: ethambutol; PZA: pyrazinamide; MXF: moxifloxacin; KM: kanamycin; PTH: prothionamide; CS: cycloserine; PAS: p-aminoslicylic acid; HD-RIF: high dose rifampin; LVFX: levofloxacin; N/A: not available; AMOX: amoxicillin/clavulanate; LZD: linezolid.